ArticleFrontiers in cellular and infection microbiology2026
HBsAg glycan isomer: a potential circulating biomarker for monitoring cccDNA and predicting virologic response in chronic hepatitis B.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous research has identified that Hepatitis B surface antigen glycan isomer (HBsAgGi) specifically marks O-glycosylated M-HBsAg exclusively present on infectious Dane particles (unlike total HBsAg, which is dominated by non-infectious subviral particles), it offers a more specific association with infectious viral burden and cccDNA activity. Accordingly, the present study aims to assess the potential of HBsAgGi as a circulating biomarker to reflect intrahepatic covalently closed circular DNA (cccDNA) and transcriptional activity, and for monitoring antiviral response. Methods: A total of 73 individuals diagnosed with chronic genotype C HBV infection were recruited for this study. Serum concentrations of HBsAgGi, HBsAg, HBeAg, HBV DNA, and HBV RNA were measured. Intrahepatic cccDNA and HBV RNA loads were determined in liver biopsy specimens obtained from 16 patients. Correlations between serum HBsAgGi and intrahepatic markers were analyzed. We measured serum Hepatitis B core-related antigen (HBcrAg) levels in 28 patients. 18 patients received nucleos(t)ide analogue therapy for 48 weeks and we evaluated levels of HBsAgGi after therapy. Additionally, receiver operating characteristic (ROC) curve analysis was conducted to assess the discriminative ability of the candidate biomarkers in predicting virological response (VR). Results: Serum HBsAgGi demonstrated significant positive correlations with intrahepatic cccDNA (r = 0.7172, Conclusion: Serum HBsAgGi represents an emerging, minimally invasive serum indicator for assessing intrahepatic cccDNA loads and viral transcriptional activity, demonstrating stronger correlations with intrahepatic markers compared to conventional serum markers in this cohort. It also shows promising utility for predicting treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.